Investigating how a specific vaccine can stop early SIV infections in monkeys
Project 2: Characterization of the in vivo T cell (and overall immune) interception of primary SIV infection after vaccination with differentially response programmed RhCMV/SIV vectors
This study is testing a new vaccine that uses a virus from monkeys to see if it can help boost the immune system in Rhesus macaques and stop the early spread of SIV, which is similar to HIV, with the hope that what we learn can help create better vaccines for people.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10895458 on NIH RePORTER |
What this research studies
This research focuses on how a vaccine using Rhesus Cytomegalovirus vectors can stimulate the immune system in Rhesus macaques to effectively halt the early spread of SIV infections. The study examines the immune responses generated by this vaccine, particularly the role of CD8+ T cells and their ability to recognize and respond to the virus. By understanding the mechanisms behind this immune interception, researchers aim to identify the characteristics that lead to successful replication arrest of the virus. The findings could provide insights into developing effective vaccines for similar infections in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at high risk for HIV infection who may benefit from innovative vaccine strategies.
Not a fit: Patients who are already HIV positive or have advanced HIV disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of vaccines that effectively prevent the early stages of SIV infection, potentially translating to HIV prevention in humans.
How similar studies have performed: Previous research has shown promising results with similar vaccine approaches in animal models, indicating potential for success in this area.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Hansen, Scott G — Oregon Health & Science University
- Study coordinator: Hansen, Scott G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.